Amgen, Inc. has secured a several month lead with its newly approved Lumakras (sotorasib) as the only KRAS G12C inhibitor available in the US before its likely first competitor, adagrasib from Mirati Therapeutics, Inc., hits the market. Even so, Amgen executive vice president of global commercial operations Murdo Gordon told Scrip that the company still faces the tough challenge of launching its new drug during the COVID-19 pandemic.
The US Food and Drug Administration approved Lumakras (sotorasib) on 28 May for the treatment of KRAS G12C-mutated locally advanced...






